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ABSTRACT: Five new polyketides, asperochrapyran (1) and
asperochralactones A−D (2−5), along with 12 known polyketides
(6−17), were obtained from the fungal strain Aspergillus
ochraceopetaliformis. Structures of all isolates were elucidated by
their spectroscopic parameters. The relative configurations of the
new compounds were deduced by the data of coupling constants
and NOESY spectra. The absolute configurations were determined
by the comparison of experimental and calculated ECD spectra.
Moreover, the plausible biosynthesis pathway of major isolates was
proposed as well. Anti-inflammatory activity of compounds 5 and
7−17 were evaluated with human neutrophils in response to the
stimulation of formyl-methionyl-leucyl phenylalanine (fMLP).
Asperlactone (9), aspyrone (13), and (−)-(3R)-mellein (14)
exerted superoxide anion inhibition at 30 ± 9%, 29 ± 9%, and 26 ± 12%, respectively, at 10 μM. The capacities of asperlactone (9),
aspilactonol B (10), penicillic acid (12), and (−)-(3R)-mellein (14) in elastase release inhibition were revealed as 25 ± 4%, 38 ±
8%, 25 ± 5%, and 34 ± 9%, respectively, at 10 μM.
■ INTRODUCTION
Fungi generate diverse groups of secondary metabolites with
intriguing activities.1 Several bioactive secondary metabolites
have been applied in agriculture or pharmaceutical industries.1
Following the cooperation of a high-throughput screening
project with the Dr. Cecilia Koo Botanic Conservation Center
(KBCC) in Taiwan providing extraordinary plant materials, we
obtained a fungal strain, isolated from leaves of Anthurium
brownii (A. brownii) Mast, which was identified as Aspergillus
ochraceopetaliformis (A. ochraceopetaliformis) Bat. and Maia.
The Aspergillus genus contains a large number of species and is
widely distributed in natural environments. This genus was
reported as a prolific source in producing bioactive secondary
metabolites, such as alkaloids,2 glycosides,3 peptides,4 poly-
ketides,5 steroids,6 and terpenoids.7 These molecules exhibited
diverse biological activities, including antibacterial,8,9 anti-
fungal,10 cytotoxic,11 nematicidal,12 radical scavenging,13
ovicidal, and insect growth-regulating14 activities. The
chemical diversity and broad spectrum of bioactivities make
this genus to be a potential resource in the discovery of new
drug development. For instance, the renowned case of
cholesterol-lowing drug, lovastatin, was discovered from
Aspergillus terreus (A. terreus). It was proved as a trigger of
HMG-CoA reductase inhibition and clinically used as a
hypercholesterolemia and cardiovascular disease ameliorator.15
Moreover, simvastatin, a derivative synthesized and modified
substance generated from A. terreus, is another clinical drug
used for a similar purpose of lovastatin.15 These cases attracted
our attention and encouraged us on exploring new potential
bioactive molecules from the Aspergillus genus.
Although A. ochraceopetaliformis was considered as not a
common pathogen to humans, it had once been found in
human skin lesions and reported as an invader to cause
onychomycosis.16,17 Notably, this fungal species was also found
in ocean sponges and even discovered from an Antarctic soil
sample.5,18,19 Furthermore, Wang et al. reported that this
fungal species would produce various types of bioactive
sesquiterpenoids with fascinating activities such as those
against of influenza viruses or lipopolysaccharide-induced
NO release in RAW 264.7 cell lines.5,18
In a current study, we fermented A. ochraceopetaliformis
through a liquid fermentation methodology and the ethyl
acetate extract of A. ochraceopetaliformis was found to possess
an anti-inflammatory effect on inhibiting superoxide anion
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generation and elastase release at 10 μg/mL (103 ± 1% and
107 ± 6%, respectively).
Continuing our efforts on discovery of the chemical diversity
and biological activities of natural products, we performed
further chemical and biological investigation on this fungus and
identified 17 polyketide secondary metabolites, including 5
new polyketides (1−5) and 12 known polyketides (6−17).
Herein, we described the structural elucidation of new
secondary metabolites (1−5) and the extensive determination
of the absolute configurations by computational approaches.
We evaluated the isolated compounds for several bioactivity
assays, including those for cytotoxicity and anti-inflammatory
properties. Moreover, we proposed the plausible biosynthesis
pathway of the isolated polyketide secondary metabolites.
■ RESULTS AND DISCUSSION
Five new polyketides, asperochrapyran (1) and asperochra-
lactones A−D (2−5), together with 12 known polyketides,
(5S,6R,8S,9R)-8,9-dihydroxy-8,9-deoxyaspyrone (6), aspyro-
nol (7), dihydroaspyrone (8), asperlactone (9), aspilactonol
B (10), asperochrin B (11), penicillic acid (12), aspyrone
(13), (−)-(3R)-mellein (14), aspinonediol (15), aspinotriols
A (16), and aspinotriols B (17) were isolated from the ethyl
acetate extract of A. ochraceopetaliformis (Figure 1). New
compounds were elucidated and identified by their spectro-
scopic data as well as by analyzing their stereochemistries with
experimental and electronic circular dichroism (ECD)
calculations and conformational searches to establish their
absolute configurations.
Asperochrapyran (1) was obtained as a colorless oil with a
specific rotation of [α]D
24 = −83 (c 0.08, MeOH). The
molecular formula (C10H16O5) was confirmed by the analysis
of its 13C NMR and HR-ESI-MS data (m/z 239.08887 [M +
Na]+), implying 3 degrees of unsaturation. The infrared (IR)
spectrum presented prominent absorption bands for hydroxyl
(3415 cm−1), conjugated ester carbonyl (1708 cm−1), and C−
O functional groups (1087 cm−1). The UV spectrum showed
an absorption at 218 nm. The 1H NMR data of 1 (Table 1)
indicated two methyls at δH 1.18 (d, J = 6.5 Hz) and 1.29 (d, J
= 7.0 Hz), one olefinic methane at δH 6.88 (dd, J = 2.3, 1.6
Hz), two oxymethines at δH 3.67 (q, J = 6.5 Hz) and 4.53
(qdd, J = 7.0, 3.8, 3.4 Hz), one methoxy at δH 3.75 (s), and
one methylene at δH 2.26 (ddd, J = 17.6, 3.4, 1.6 Hz) and 2.31
(ddd, J = 17.6, 3.8, 2.3 Hz). Moreover, the 13C NMR and
DEPT data (Table 1) revealed 10 carbon signals. These signals
resulted from one ester carbonyl (δC 168.5), one olefinic
methine (δC 141.7), one nonprotonated sp
2 carbon (δC 126.4),
one hemiacetal carbon (δC 97.9), two oxygenated methines
(δC 66.1 and 73.5), one methylene (δC 29.9), one methoxy (δC
52.3), and two methyls (δC 16.7 and 20.1). According to its
MS and NMR data, 2 degrees of unsaturation, CC double
bond and carbonyl functionalities, were disclosed and reduced
to one degree of unsaturation. By comparing these data with a
previous study, 1 would be inferred as a polyketide framework
secondary metabolite.20
In interpretation of the COSY spectrum, two fragments, H-4
(δH 6.88)/H2-5 (δH 2.26 and 2.31)/H-6 (δH 4.53)/H-7 (δH
1.29) and H-9 (δH 3.67)/H-10 (δH 1.18), were observed
(Figure 2). The HMBC correlations were found from H2-5 to
C-3 (δC 126.4). These correlations established a 3,6-dihydro-
2H-pyran ring system. The side-chain moiety of C-9 (δC 73.5)
and C-10 (δC 16.7) was linked to the pyran ring by HMBC
cross peaks from both H-9 and H-10 to C-2 (δC 97.9). Further,
the HMBC correlations from 8-OMe (δH 3.75), and H-4 (δH
6.88) to C-8 (δC 168.5) were used to predict the linkage of
ester carbonyl to C-3 (δC 126.4) (Figure 2). Based on the
above data, the gross structure of 1 was established.
In terms of the stereochemistry of 1, the C-6 can be scripted
by the coupling constants (J5,6 = 3.8 and 3.4 Hz). As a result,
the H-6 and CH3-7 were sited in pseudo-equatorial and
pseudo-axial positions, respectively. All the possible absolute
results of 1, 2S,6S,9S-1, 2R,6R,9R-1, 2S,6R,9S-1, 2R,6S,9R-1,
2S,6S,9R-1, 2R,6R,9S-1, 2S,6R,9R-1, and 2R,6S,9S-1, were
computed by the conformational search algorithms. The
experimental J5,6 coupling constants of these conformers are
composed with an anti and a gauche orientation. However, the
calculated results showed the data with both gauche
orientations. Hence, the prediction of calculated conformers,
2S,6S,9S-1, 2R,6R,9R-1, 2S,6S,9R-1, and 2R,6R,9S-1, cannot
match to the J5,6 coupling constants. On the other hand, all the
other conformers, such as 2S,6R,9S-1, 2R,6S,9R-1, 2S,6R,9R-1,
and 2R,6S,9S-1, not only conform with the J5,6 coupling
constants but also meet the data of the absence in NOESY
correlation between H3-7 and H-10 (Figure S6). Thus, the
absolute configuration of 1 was further determined by
comparing the calculated and experimental ECD spectra with
Gaussian 09 software. The ECD spectra of possible con-
formers, 2S,6R,9S-1, 2R,6S,9R-1, 2S,6R,9R-1, and 2R,6S,9S-1,
are shown in Figure 3. The experimental ECD spectrum of 1
was approximate to 2R,6S,9S-1, which exhibited a calculated
ECD spectrum with positive Cotton effects at 240 and 270 nm
and negative Cotton effects at 223 and 246 nm. Therefore, the
structure and absolute stereochemistry of 1 were completely
elucidated as descripted, and it was named asperochrapyran
(1).
Asperochralactone A (2) was isolated as a colorless oil, and
the high-resolution ESI-MS data showed a molecule peak at
m/z 239.08889 [M + Na]+, which indicated the molecular
formula as C10H16O5 and 3 as the index of hydrogen
deficiency. The γ-lactone, ketone, and C−O signals were
found in the IR spectrum at 1766, 1720, and 1078 cm−1,
respectively. In the 1H NMR spectrum of 2 (Table 1), the
proton resonances suggested two methyls at δH 1.43 (d, J = 7.2
Hz) and 1.56 (d, J = 6.4 Hz), three oxymethines at δH 3.65
Figure 1. Structures of all isolates (1−17).
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(dd, J = 7.6, 6.4 Hz), 4.32 (q, J = 7.2 Hz), and 4.38 (quint, J =
6.4 Hz), one methylene at δH 2.93 (dd, J = 17.6, 4.8 Hz) and
3.09 (J = 17.6, 4.8 Hz), one methine at δH 3.01 (dt, J = 7.6, 4.8
Hz), and one methoxy at δH 3.41 (s). Furthermore, the
13C
and DEPT NMR data of 2 (Table 1) denoted one carbonyl
(δC 210.0), one ester carbonyl (δC 175.2), three oxygenated
methines (δC 72.9, 79.9, and 86.7), one methoxy (δC 58.5),
one methylene (δC 36.0), one methine (δC 43.7), and two
methyls (δC 20.0 and 20.2). According to the measured IR,
MS, NMR, and UV (212 nm) spectral data analysis and
referring to a previous report,20 compound 2 was identified as
a polyketide secondary metabolite with 3 unsaturated degrees
counted in γ-lactone and ketone moieties.
The COSY correlations between H2-7 (δH 2.93 and 3.09)/
H-3 (δH 3.01)/H-4 (δH 3.65)/H-5 (δH 4.38)/H3-6 (δH 1.56)
and H-9 (δH 4.32)/H3-10 (δH 1.43) indicated two partial
fragments (Figure 2). The HMBC correlations of H2-7/C-2
(δC 175.2) and 4-OMe (δH 3.41)/C-4 (δC 86.7) and
aforementioned COSY fragments were used to elaborate the
γ-lactone moiety (Figure 2). Moreover, the HMBC corre-
spondence from H2-7 and H3-10 to C-8 (δC 210.0) and the
remaining COSY fragment suggested the connection with the
γ-lactone moiety (Figure 2). Thus, the planar structure of 2
was established. Additionally, the NOESY correlation of H-3/
H-4/H-5 was observed (Figure S12), which indicated that
those protons were at the same orientation.
Table 1. 1H (400 MHz) and 13C (100 MHz) NMR Spectroscopic Data of Compound 1 in CD3OD and Compounds 2, 4, and 5
in CDCl3;
1H (600 MHz) and 13C (150 MHz) NMR Spectroscopic Data of Compound 3 in CDCl3
1 2 3 4 5
no. δH (J in Hz) δC δH (J in Hz) δC δH (J in Hz) δC δH (J in Hz) δC δH (J in Hz) δC
2 97.9, C 175.2, C 175.8, C 169.7, C 165.8, C
3 126.4, C 3.01, dt (7.6,
4.8)
43.7,
CH
3.08, dt (6.6,
4.6)
41.1,
CH
126.8, C 129.7, C
4 6.88, dd (2.3, 1.6) 141.7,
CH
3.65, dd (7.6,
6.4)
86.7,
CH
3.90, t (6.6) 81.5,
CH
7.00, dd (6.6,
1.8)
150.1,
CH
6.84, dd (2.6,
0.8)
147.7,
CH
5 4.38, quint
(6.4)
79.9,
CH
4.80, quint
(6.6)
77.5,
CH
4.65, quint
(6.6)
66.5, CH 4.23, dd (8.5,
2.6)
68.4, CH
5a 2.31, ddd (17.6, 3.8,
2.3)
29.9,
CH2
5b 2.26, ddd (17.6, 3.4,
1.6)
6 4.53, qdd (7.0, 3.8,
3.4)
66.1, CH 1.56, d (6.4) 20.2,
CH3
1.38, d (6.6) 14.3,
CH3
1.39, d (6.6) 22.9,
CH3
4.33, dq (8.5,
6.3)
80.8, CH
7 1.29, d (7.0) 20.1,
CH3
4.81, dd (1.8,
1.8)
74.8, CH 1.43, d (6.3) 18.4,
CH3
7a 3.09, dd (17.6,
4.8)
36.0,
CH2
3.02, dd (18.2,
4.6)
35.5,
CH2
7b 2.93, dd (17.6,
4.8)
2.82, dd (18.2,
4.6)
8 168.5, C 210.0, C 209.8, C 4.33, dd (4.5,
1.8)
85.2, CH 3.89, dd (4.4,
0.8)
83.5, CH
9 3.67, q (6.5) 73.5, CH 4.32, q (7.2) 72.9,
CH
4.29, q (7.1) 73.1,
CH
3.95, qd (6.6,
4.5)
67.8, CH 3.80, qd (6.4,
4.4)
70.2, CH
10 1.18, d (6.5) 16.7,
CH3
1.43, d (7.2) 20.0,
CH3
1.43, d (7.1) 19.9,
CH3
1.33, d (6.6) 18.9,
CH3
1.17, d (6.4) 19.5,
CH3
4-OMe 3.41, s 58.5,
CH3
3.39, s 58.1,
CH3
7-OMe 3.42, s 55.7,
CH3
8-OMe 3.75, s 52.3,
CH3
3.32, s 57.9,
CH3
9-OH 3.25, br s
Figure 2. Key COSY (1H−1H) and HMBC (H → C) correlations of
1−5.
Figure 3. Calculated and experimental ECD spectra of 1.
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The absolute configuration was elucidated with ECD
spectroscopies. Four possible candidates, 3S,4R,5R,9S-2,
3R,4S,5S,9S-2, 3R,4S,5S,9R-2, and 3S,4R,5R,9R-2, were
computed by molecular modeling software, Spartan 16, to
conduct the results of the conformation search. ECD spectra of
each conformer were further calculated by Gaussian 09 as well.
The results showed that the experimental ECD spectrum
exhibited positive Cotton effects at 221 and 278 nm and
negative ones at 243, 316, and 377 nm. The data displayed
high similarity to the calculated ECD pattern of 3S,4R,5R,9S-2
(Figure S34). Therefore, the absolute stereochemistry of
compound 2 was deduced, and the name of the new
compound, asperochralactone A, was given.
Asperochralactone B (3) was purified as a colorless oil with a
specific optical rotation of [α]D
24 = −74 (c 0.03, MeOH) and
possessed a molecular formula of C10H16O5 and 3 degrees of
unsaturation deduced from HR-ESI-MS data (m/z 239.08889
[M + Na]+). Two methyl groups [δH 1.38 (d, J = 6.6 Hz) and
1.43 (d, J = 7.2 Hz)], three oxymethines [δH 3.90 (t, J = 6.6
Hz), 4.29 (q, J = 7.1 Hz), and 4.80 (quint, J = 6.6 Hz)], one
methylene [δH 2.82 (dd, J = 18.2, 4.6 Hz) and 3.02 (dd, J =
18.2, 4.6 Hz)], one methine [δH 3.08 (dt, J = 6.6, 4.6 Hz)], and
one methoxy [δH 3.39 (s)] were revealed from the
1H NMR
spectrum of 3 (Table 1). The 13C and DEPT NMR spectra of
3 (Table 1) indicated that 10 carbons can be categorized into
one carbonyl (δC 209.8), one ester carbonyl (δC 175.8), three
oxygenated methines (δC 73.1, 77.5, and 81.5), one methoxy
(δC 58.1), one methylene (δC 35.5), one methine (δC 41.1),
and two methyls (δC 14.3 and 19.9). The IR, MS, NMR, and
UV data of 3 shared high similarity to compound 2, implying
that these two molecules possess the same framework.
The relative configuration of 3 was assigned on the basis of
NOESY correlations. The NOESY cross peaks of H3-6/H-3/4-
OMe and H-4/H-5 suggested that those two groups showed
different orientations (Figure S18). The absolute configuration
of 3 was further determined by comparing the ECD spectra
between computational and experimental results to 2. Two
possible conformers, 3S,4S,5S,9S-3 and 3R,4R,5R,9S-3, were
simulated by Gaussian 09, which provided the calculated ECD
spectra (Figure S35) for conformation search. The pattern of
ECD curves of 3S,4S,5S,9S-3 demonstrated high similarity to
the experimental ECD spectrum of 3. Therefore, on the basis
of the above data, the structure of 3 was identified and named
asperochralactone B.
Asperochralactone C (4) was obtained as a colorless oil.
Three degrees of unsaturation was estimated on the basis of its
molecular formula (C10H16O5), which was determined by the
analysis of its HR-ESI-MS data (m/z 239.08889 [M + Na]+).
The hydroxyl (3420 cm−1), α,β-unsaturated-γ-lactone (1748
and 1666 cm−1),20 and C−O (1087 cm−1) signals were
observed in the IR spectrum. The 1H NMR of 4 (Table 1)
displayed two methyl groups at δH 1.33 (d, J = 6.6 Hz) and
1.39 (δH, J = 6.6 Hz), one olefinic methane at δH 7.00 (dd, J =
6.6,1.8 Hz), four oxymethines at δH 3.95 (qd, J = 6.6, 4.5 Hz),
4.33 (dd, J = 4.5, 1.8 Hz), 4.65 (quint, J = 6.6 Hz), and 4.81
(dd, J = 1.8, 1.8 Hz), and one methoxy at δH 3.42 (s). The
13C
and DEPT NMR spectra (Table 1) revealed one ester carbonyl
(δC 169.7), one olefinic methine (δC 150.1), one non-
protonated sp2 carbon (δC 126.8), four oxygenated methines
(δC 66.5, 67.8, 74.8, and 85.2), one methoxy (δC 55.7), and
two methyls (δC 18.9 and 22.9).
The 1H−1H COSY spectrum (Figure 2) showed correlations
between H-4 (δH 7.00)/H-5 (δH 4.65)/H3-6 (δH 1.39) and H-
7 (δH 4.81)/H-8 (δH 4.33)/H-9 (δH 3.95)/H3-10 (δH 1.33).
The α,β-unsaturated-γ-lactone moiety was established by the
COSY fragment (H4/H5/H3-6) and the HMBC correlations
of H-4/C-2 (δC 169.7) and H-5/C-3 (δC 126.8) (As shown in
Figure 2). Furthermore, the side-chain fragment was attached
to the α,β-unsaturated-γ-lactone by HMBC cross-peak
correlations (H-4/C-7 and H-7/C-2 and C-3). The methoxy
group was substituted to C-7, which was confirmed by an
HMBC correlation of 7-OMe/C-7. According to aforemen-
tioned data, the planar structure of 4 was determined.
The relative configuration of 4 was assigned by coupling
constant analyses and experimental ECD. According to a
previous report for xylogibloactone,20 the coupling constant of
erythro was more than 4.0 Hz and that of the threo was less
than 2.5 Hz.20,21 The coupling constants of H-7/H-8 (1.8 Hz)
and H-8/H-9 (4.5 Hz) exhibited threo and erythro relative
configurations, respectively. Notably, the absolute configura-
tion at the γ site with a methyl or methoxy substitution on α,β-
unsaturated-γ-lactone can be determined by the Cotton effect
between 200−235 and 235−270 nm. The positive Cotton
effect at 200−235 nm and a negative one at 235−270 nm
represent a β configuration, and the negative Cotton effect at
200−235 nm and a positive one at 235−270 nm show an α
configuration.22−24 According to the experimental ECD
spectra (Figure S35), the H-5 of 4 displayed an α orientation
and the configuration was in the R form. Additionally, the
calculated ECD spectra of 5R,7R,8R,9R-4 and 5R,7S,8S,9S-4
were conducted by Gaussian 09. The absolute stereochemistry
of 4 was assigned to be 5R,7S,8S,9S by ECD data (Figure S36).
Finally, the structure of compound 4 was elucidated and
named asperochralactone C.
Asperochralactone D (5) was isolated as a colorless oil. The
molecular formula of C10H16O5 was deduced for 5 based on a
pseudo ion peak at m/z 239.08881 [M + Na]+ in the HR-ESI-
MS and indicated 3 degrees of unsaturation. The IR spectrum
illustrated hydroxyl (3409 cm−1), α,β-unsaturated-δ-lactone
(1721 and 1650 cm−1),25 and C−O (1084 cm−1) function-
alities. Furthermore, in analyzing its UV (208 nm) and 1D and
2D NMR spectral data, this compound exhibited high
similarity to compound 7.20 However, the opposite optical
rotation values of compounds 5 (+64) and 7 (−41.6)20
implied that these two compounds have different stereo-
chemistries. The relative configurations of C-5, C-6, C-8, and
C-9 were further determined by coupling-constant analyses.
Considering the conformation between H-5 and H-6, the
coupling constant of the trans form was usually detected
around 7.0 Hz, and the cis form would be observed near 3.0
Hz.2,25−27 The coupling constant of H-5/H-6, calculated as 8.5
Hz, suggested the existence of a trans conformation. On the
other hand, according to previous studies, the conformation
between H-8/H-9 should be regarded as threo, while the
coupling constant was more than 6.3 Hz. Furthermore, a
coupling constant less than 5.0 Hz would be erythro.20,28−30
The J value between H-8/H-9 was found to be 4.4 Hz, and the
conformation would be considered as erythro. In addition, the
absolute configuration of 5 was elucidated by comparing the
experimental ECD spectra with the calculated results. The
experimental ECD spectrum of 5 showed a negative Cotton
effect near 270 nm (n to π*), which suggested an S
configuration at C-5,31 and C-6 was assigned to an R
configuration accordingly. Due to the relative conformation
between C-8 and C-9 assigned as erythro, the possible absolute
stereochemistry of 5 would be 5S,6R,8S,9R or 5S,6R,8R,9S.
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Compound 7 was reported to possess a 5S,6R,8S,9R
configuration,20 which implied that the structure of 5 should
be 5S,6R,8R,9S according to the aforementioned information.
In order to deduce the absolute configuration, the computa-
tional procedures were carried out. The pattern of the ECD
curve of the experimental result was approximate to the ECD
curve simulated for 5S,6R,8R,9S-5 (Figure S37) and con-
formation search result was calculated by carbon chemical
shifts (Figure S42). Consequently, the structure and absolute
configuration of 5 were elucidated, and the name asperochra-
lactone D was given.
Because the absolute configuration of compound 6 has not
been established yet,32 a series of computational experiments
were carried out for determining this issue. The experimental
ECD displayed a negative Cotton effect at 260 nm. It
suggested an S configuration at C-5. Moreover, the
experimental ECD spectrum of 6 was compared with 5
(8R,9S) and 7 (8S,9R).25 The pattern of the ECD curve of 6
exhibited high similarity to that of 7 (Figure S37). Thus, this
suggested that the absolute stereochemistry of 6 can be
assigned as 5S,6R,8S,9R and named (5S,6R,8R,9R)-8,9-
dihydroxy-8,9-deoxyaspyrone.
In this study, the conformational search was used to simulate
the dynamic balance of compounds in the solvent phase. The
conformational search conformers including structures with a
flexible chain were also considered and calculated. Due to
insufficient samples for chemical modification to help in
determination of stereochemistry, absolute configurations of
isolated compounds were speculated by spectral data.
Fungi produce many secondary metabolites that exhibit a
wide range of biological activities.33 Polyketides are a class of
fungal secondary metabolites, and many of them demonstrate
fascinating biological activities.34 Therefore, the isolated
compounds were tested for several bioactivities such as
cytotoxicity and anti-inflammation. Due to limited sample
amounts, compounds 1−4 and 6 were not able to be evaluated
in their anti-inflammation assay. Compounds 5 and 7−17 were
tested for anti-inflammation activity against the response of
human neutrophils stimulated by formyl-methionyl-leucyl
phenylalanine (fMLP). Compounds 9, 13, and 14 exerted an
anti-inflammatory effect on inhibiting superoxide anion
generation with 30 ± 9%, 29 ± 9%, and 26 ± 12%,
respectively, at a concentration of 10 μM (Table 2).
Furthermore, the capacities of elastase release inhibition after
administrations of compounds 9, 10, 12, and 14 were revealed
as 25 ± 4%, 38 ± 8%, 25 ± 5%, and 34 ± 9%, respectively, at a
concentration of 10 μM (Table 2). In these assays, LY294002
was taken as the positive control and showed 99 ± 1%
superoxide anion inhibition and 73 ± 1% elastase release
inhibition at a concentration of 10 μM.35
In addition, the cytotoxicity of compounds 1−17 was
evaluated against three human cancer cell lines, including
HepG2 (hepatoma), MDA-MB-231 (human breast carcino-
ma), and A549 (human lung adenocarcinoma). Compounds 9
and 12 were active in the cytotoxicity evaluation against the
HepG2 cancer cell line (IC50 = 42.9 ± 0.5 and 32.9 ± 0.0 μM,
respectively). Moreover, compound 12 displayed cytotoxic
activity against MDA-MB-231 and A549 cancer cell lines with
the IC50 values of 39.4 ± 0.0 and 25.9 ± 1.8 μM, respectively
(Table 3).
The plausible biosynthesis pathway (Figure 4) was proposed
in that compounds 1−7, 11, and 13 were composed of 3-
oxobutanoic acid with 3,5-dioxohexanoic acid or 3-oxopenta-
noic acid. All new compounds were derived from the
polyketide synthase (PKS) pathway with a series of
condensation, cyclization, decarbonation (acetyl-CoA carbox-
ylase), dehydration (dehydratase), methylation (methyl trans-
ferase), reduction (enoyl reductase), and oxidation (oxi-
dase).36
■ CONCLUSIONS
In the current study, five new polyketides, asperochrapyran (1)
and asperochralactones A−D (2−5), together with 12 known
secondary metabolites (6−17) were isolated from the fungal
strain A. ochraceopetaliformis. The structure of each new
compound possesses at least three chiral centers, which causes
difficulty to determine their absolute stereochemistry. Previous
research had never reported the determination of the absolute
configurations from this type of polyketide secondary
metabolites. Thus, this unusual issue is an imperative task
that needs to be clarified. Additionally, the new compounds
exhibited an oil-like appearance, whose configurations are
difficult to elucidate by a single crystal X-ray analysis method.
Therefore, coupling constant, NOESY, experimental, and
calculated ECD spectroscopic analyses were used extensively
to assign the absolute configuration. Our findings suggested
the stereochemistry in a series of special fungal polyketide
secondary metabolites, and the plausible biosynthesis pathway
of key isolates was proposed.
■ MATERIALS AND METHODS
General Experimental Procedures. Polymerase chain
reaction (PCR) amplifications were reacted by FlexCycler
PCR. Optical rotations were measured with a JASCO P-2000
Table 2. Anti-Inflammatory Results of Compounds 5 and
7−17
compound
superoxide anion inhibition
(%)
elastase release inhibition
(%)
5 0 ± 6 14 ± 5*
7 16 ± 8 12 ± 6
8 2 ± 3 11 ± 3*
9 30 ± 9* 25 ± 4
10 8 ± 3 38 ± 8**
11 8 ± 6 21 ± 7
12 3 ± 1** 25 ± 5
13 29 ± 9* 12 ± 8
14 26 ± 12 34 ± 9
15 7 ± 6 1 ± 5
16 0 ± 6 17 ± 6
17 13 ± 3 * 1 ± 8
LY294002a 99 ± 1*** 73 ± 1***
aLY294002 was used as the positive control.35 Percentage of
inhibition (Inh %) at 10 μM concentration. Results are presented
as mean ± SEM (n = 3−4). *P < 0.05, **P < 0.01 compared with the
control (DMSO).
Table 3. Cytotoxicity Results (IC50, μM)
a
compoundb HepG2 MDA-MB-231 A549
9 42.9 ± 0.5 >100 >100
12 32.9 ± 0.0 39.4 ± 0.0 25.9 ± 1.8
doxorubicinc 0.4 ± 0.0 0.8 ± 0.2 0.2 ± 0.0
aIC50 values are taken as mean ± SD (n = 3).
bCompounds 1−8, 10−
11, and 13−17 were inactive with IC50 values of >100 μM. cPositive
control.
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polarimeter. UV spectra were recorded on a JASCO V-530
UV−vis spectrophotometer, and experimental ECD spectra
were measured on a JASCO J-815 spectropolarimeter. IR
spectra were obtained on a JASCO FT/IR-4600 Fourier
transform infrared spectrometer. 1D and 2D NMR spectra
were performed on a JEOL JNM-ECS 400 MHz NMR
spectrometer (1H, 400 MHz; 13C, 100 MHz), Varian Mercury
Plus 400 MHz FT-NMR (1H, 400 MHz; 13C, 100 MHz), and
Varian VNMRS 600 MHz FT-NMR (1H, 600 MHz; 13C, 150
MHz) in CDCl3, CD3OD, and CD3COCD3, respectively. Mass
spectra were obtained from a Waters 2695 separation module
(ESI-MS) and Bruker FT-MS SolariX (HR-ESI-MS). Column
chromatography was carried out on silica gel 60 (0.063−0.200
mm and 0.040−0.063 mm, Merck) and Sephadex LH-20 (Fine
Chemicals AB, Uppsala, Pharmacia). Thin-layer chromatog-
raphy (TLC) analyses were performed using silica gel 60,
F254, and RP-18, F254S (0.20 nm, Merck, Germany). Semi-
preparative HPLC was performed on Shimadzu LC-10 AD,
Shimadzu LC-20AT, or Jasco PU-980 pumps, an SPD-M10A
diode array, SPD-10A UV−vis or UV-970 UV−vis detectors,
and SCL-10A or CBM-20A controllers with Luna phenyl-
hexyl, 100 Å, 250 × 10 mm, Phenomenex or Luna CN, 100 Å,
250 × 10 mm, Phenomenex columns.
Fungal Material. The fungus, A. ochraceopetaliformis, was
isolated from A. brownii collected from the Dr. Cecilia Koo
Botanic Conservation Center (KBCC), Pingtung, Taiwan.
KBCC is the biggest botanical garden and deposits over 30,000
living plant materials. The leaves of A. brownii were washed
and air-dried. The dry leaves were soaked in 0.01% Tween 20
(aq), ddH2O, and 0.01% bleach (aq) to clean the surface. The
washed leaves were moved into a laminar flow after the
treatment of 75% alcohol (aq), and we used sterilized scissors
and tweezers to cut the central part of leaf (5 mm × 5 mm).
The mesophyll of the leaf was bisected and seeded on the
potato dextrose agar (PDA) plate. Then, the plates were
incubated in a 25 °C incubator. After repeated purification, the
pure strains were stored in 2 mL cryogenic vials (Nalgene,
Thermo) with 1.5 mL of potato dextrose broth (PDB) and 0.2
mL of sterilized glycerol and stored in a −80 °C refrigerator.
The fungal strain was identified by D.-Y.Y. and C.-Y.L. A
voucher specimen (code no. K004643) was deposited in the
Graduate Institute of Natural Products, College of Pharmacy,
Kaohsiung Medical University, Kaohsiung, Taiwan.
Species Identification. The fungus A. ochraceopetaliformis
was identified on the basis of its morphology and a pair of
internal transcribed spacers (ITS1-5.8S-ITS2) rRNA gene
analysis using universal fungal primers. DNA was extracted by
using the AxyPrep Multisource Genomic DNA miniprep kit
(AxyPrep, #02815KC1) following the manufacturer’s protocol.
PCR amplifications were accomplished by using FlexCycler2
(Analytik Jena, Germany) with the following conditions: 95 °C
(5 min), 30 cycles of 95 °C (30 s), 55 °C (30 s), and 72 °C
(40 s), with the last extension at 72 °C (7 min). The PCR
products were sent to the Mission Biotech Co., Ltd. for
sequencing services after purification. The results of 18S rRNA
gene sequences were blasted with the National Center for
Biotechnology Information (NCBI) database for species
identification. The reversal and forwarding of the 18S rRNA
gene sequence displayed 99% sequence identity with A.
ochraceopetaliformis (GenBank accession no. FJ7976981).
Fermentation, Extraction, and Isolation. The fungus A.
ochraceopetaliformis was cultivated by using 120 Erlenmeyer
flasks (500 mL) with each flask containing 300 mL of PDB
medium. These flasks were incubated on the rotator shaker at
150 rpm at 25 °C for 7 days. The whole broth was filtered to
give the filtrate from mycelia. The filtrate was extracted by
ethyl acetate (EtOAc), and the EtOAc layer was concentrated
by rotary evaporators to obtain the crude extract (10.9 g). The
crude extract was loaded to the Sephadex LH-20 column and
eluted with methanol (MeOH) to yield five fractions (Fr. 1−
5). Compound 1425 (3.8 mg) was precipitated from Fr. 5. Fr. 3
was isolated by a silica gel column stepwise eluted with
dichloromethane (CH2Cl2) and MeOH from 29:1 to 0:1 to
give 10 fractions (Fr. 3.1−3.10). Fr. 3.3 was further separated
Figure 4. Plausible biosynthesis pathway of new compounds and their analogues.
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by a silica gel column eluted with CH2Cl2 and MeOH from
24:1 to 0:1 to furnish nine fractions (Fr. 3.3.1−3.3.9). Fr. 3.3.5
(100.4 mg) was purified by reversed-phase (RP) HPLC (Luna
phenyl-hexyl, 100 Å, 250 × 10 mm, Phenomenex, flow rate of
2.0 mL/min, 35% MeOH (aq)) to afford compounds 925 (20.4
mg) and 1312 (4.5 mg). Fr. 3.5 was submitted to silica gel
column chromatography eluted with CH2Cl2 and MeOH from
39:1 to 0:1 to get 10 fractions (Fr. 3.5.1−3.5.10). Fr. 3.5.5
(16.8 mg) was subjected to RP-HPLC (Luna phenyl-hexyl,
100 Å, 250 × 10 mm, Phenomenex, flow rate of 2.0 mL/min,
32% MeOH (aq)) to give compound 2 (1.0 mg). Fr. 3.5.6
(80.3 mg) was isolated by RP-HPLC (Luna phenyl-hexyl, 100
Å, 250 × 10 mm, Phenomenex, flow rate of 2.0 mL/min, 33%
MeOH (aq)) to yield compound 118 (3.2 mg) and three
fractions (Fr. 3.5.6.2−3.5.6.4). Compound 3 (1.1 mg) was
purified by normal-phase (NP) HPLC (Luna CN, 100 Å, 250
× 10 mm, Phenomenex, flow rate of 2.0 mL/min, hexanes and
EtOAc = 1:1). Fr. 3.5.7 (85.3 mg) was isolated by RP-HPLC
(Luna phenyl-hexyl, 100 Å, 250 × 10 mm, Phenomenex, flow
rate of 2.0 mL/min, 40% MeOH (aq)) to obtain compounds 1
(1.6 mg) and 1212 (56.2 mg). Fr. 3.5.9 was separated by a silica
gel column (CH2Cl2 and MeOH from 24:1 to completely
MeOH) to give eight fractions (Fr. 3.5.9.1−3.5.9.8).
Compounds 4 (2.5 mg), 5 (4.8 mg), and 722 (3.0 mg) were
isolated by RP-HPLC (Luna phenyl-hexyl, 100 Å, 250 × 10
mm, Phenomenex, flow rate of 2.0 mL/min, 25% MeOH (aq))
from Fr. 3.5.9.5 (36.1 mg). Furthermore, Fr. 3.7 (107.7 mg)
was subjected to RP-HPLC (Luna phenyl-hexyl, 100 Å, 250 ×
10 mm, Phenomenex, flow rate of 2.0 mL/min, 25%
MeOH(aq)) to afford compounds 8
37 (30.4 mg) and 1511
(1.6 mg). Compounds 632 (3.0 mg), 1035 (1.6 mg), 1611 (6.4
mg), and 1711 (6.5 mg) were purified by RP-HPLC (Luna
phenyl-hexyl, 100 Å, 250 × 10 mm, Phenomenex, flow rate of
2.0 mL/min, 15% MeOH (aq)) from Fr. 3.9 (98.9 mg).
Asperochrapyran (1): colorless oil; [α]D
24 = −83 (c 0.08,
MeOH); UV (MeOH)λmax (log ε) 218 (4.00) nm; ECD (6.5 ×
10−5 M, MeOH)λmax (Δε): 289 (−0.25), 265.5 (+0.19), 251.0
(−0.95), 223.5 (−2.71) nm; IR (ATR) vmax: 3415, 2979, 2918,
1708, 1659, 1557, 1438, 1263, 1235, 1087, 885 cm−1; 1H and
13C NMR spectroscopic data, see Table 1; HR-ESI-MS m/z
239.08887 [M + Na]+ (calcd for C10H16O5Na, 239.08899).
Asperochralactone A (2): colorless oil; [α]D
24 = −53 (c 0.06,
MeOH); UV (MeOH)λmax (log ε) 212 (3.92) nm; ECD (6.5 ×
10−5 M, MeOH)λmax (Δε): 279.5 (+0.57), 242.5 (−1.03),
221.0 (+1.01) nm; IR (ATR) vmax: 3381, 2928, 2898, 1766,
1720, 1449, 1282, 1189, 1140, 1078, 883 cm−1; 1H and 13C
NMR spectroscopic data, see Table 1; HR-ESI-MS m/z
239.08905 [M + Na]+ (calcd for C10H16O5Na, 239.08899).
Asperochralactone B (3): colorless oil; [α]D
24 = −74 (c 0.03,
MeOH); UV (MeOH)λmax (log ε) 212 (3.91) nm; ECD (6.5 ×
10−5 M, MeOH)λmax (Δε): 310 (−0.50), 274 (+1.23), 237.0
(−0.09), 220.5 (+0.72), 207 (−0.23) nm; IR (ATR) vmax:
3414, 2979, 2920, 1762, 1716, 1650, 1455, 1373, 1234, 1082,
889 cm−1; 1H and 13C NMR spectroscopic data, see Table 1;
HR-ESI-MS m/z 239.08889 [M + Na]+ (calcd for
C10H16O5Na, 239.08899).
Asperochralactone C (4): colorless oil; [α]D
24 = −26 (c 0.05,
MeOH); UV (MeOH)λmax (log ε) 215 (3.64) nm; ECD (6.5 ×
10−5 M, MeOH)λmax (Δε): 263.5 (+0.30), 228.0 (−1.05) nm;
IR (ATR) vmax: 3420, 2978, 2916, 1748, 1666, 1584, 1401,
1382, 1234, 1087, 883 cm−1; 1H and 13C NMR spectroscopic
data, see Table 1; HR-ESI-MS m/z 239.08882 [M + Na]+
(calcd for C10H16O5Na, 239.08899).
Asperochralactone D (5): colorless oil; [α]D
24 = +64 (c 0.05,
MeOH); UV (MeOH)λmax (log ε) 208 (4.24) nm; ECD (6.5 ×
10−5 M, MeOH)λmax (Δε): 270.0 (−8.55), 236.0 (+7.53), 212
(−1.55) nm; IR (ATR) vmax: 3409, 2987, 2912, 1721, 1650,
1446, 1378, 1232, 1084, 1042, 888 cm−1; 1H and 13C NMR
spectroscopic data, see Table 1; HR-ESI-MS m/z 239.08881
[M + Na]+ (calcd for C10H16O5Na, 239.08899).
In Silico Calculations. Structures were built, and we
optimized the minimized energy conformers in the MM2 level.
After the gross optimization, the data were used to output xyz
type files and input files for calculating conformational results
at MMFF94 by Spartan 16 software (Wavefunction Inc.;
Irvine, CA, U.S.A.). These data were submitted into Gaussian
09 software (Gaussian Inc.; Wallingford, CT, U.S.A.) and
optimized using the time-dependent density functional theory
(TDDFT) methodology at the B3LYP/6-311++G(d,p) level
for ECD and the GIAO-DFT at the mpw1pw91/6-311+g-
(2d,p) level for NMR in the solvent phase. During the
computation of Gaussian 09 software, the calculated ECD and
NMR spectra were generated by GaussSum 2.2.5 and
GaussView 5.0.8, respectively. TMS was calculated at the
same level of theory (δref = 183.143 ppm) as the reference
compound for the calculated NMR spectra. For conforma-
tional searches, the calculated ECD and NMR spectra of
compounds were averaged by the proportion of each
conformer.38
Anti-inflammatory Activity Assay. The assay on super-
oxide anion generation and elastase release in response to
fMLP stimulation of neutrophils was evaluated by the methods
published by a co-author of this study, T.-L.H.39
Cytotoxicity Assay. The method for cytotoxicity assay was
performed as previously described.40,41 Briefly, three human
cancer cell lines, HepG2 (1 × 104 cells), A549 (5 × 103 cells),
and MDA-MB-231 (1 × 104 cells), were inoculated onto 96-
well plates and treated with the samples (20 μg/mL). The
medium was removed after 72 h of incubation then the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
solution (100 μL, 0.5 mg/mL) was added into each well. Then,
the plates were incubated at 37 °C for 1 h. The MTT dye was
detected by the addition of 100 μL of dimethyl sulfoxide. The
absorbance was estimated at 550 nm. The positive control was
doxorubicin.
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